1887

Journal of General Virology header logo

Volume 78, Issue 12

Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions Free

Abstract

The immunogenicity and protective efficacy of recombinant vaccinia viruses (rVV) encoding the F, G, N or M2 (22K) proteins of bovine respiratory syncytial virus (BRSV) were evaluated in calves, the natural host for BRSV. Calves were vaccinated either by scarification or intratracheally with rVV and challenged 6 to 7 weeks later with BRSV. Although replication of rVV expressing the F protein in the respiratory tract was limited after intratracheal vaccination, the levels of serum and pulmonary antibody were similar to those induced following scarification. The serum antibody response induced by the F protein was biased in favour of IgG1 antibody, whereas the G and the N proteins induced similar levels of IgG1:IgG2, and antibody was undetectable in calves primed with the M2 protein. The F protein induced neutralizing antibodies, but only low levels of complement-dependent neutralizing antibodies were induced by the G protein, and antibody induced by the N protein was not neutralizing. The F and N proteins primed calves for BRSV-specific lymphocyte proliferative responses, whereas proliferative responses were detected in calves primed with the G protein only after BRSV challenge. The M2 protein primed lymphocytes in only one out of five calves. Although there were differences in the immune responses induced by the rVVs, the F, G and N, but not the M2, proteins induced significant protection against BRSV infection and, in contrast with the enhanced lung pathology seen in mice vaccinated with rVV expressing individual proteins of human (H)RSV, there was a reduction in lung pathology in calves.

  • Published Online:
© Society for General Microbiology Ltd 1997
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-12-3195
1997-12-01
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/12/9400970.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-12-3195&mimeType=html&fmt=ahah

References

  1. Aherne W., Bird T., Court S. D. M., Gardner P. S., McQuillin J. 1970; Pathological changes in virus infections of the lower respiratory tract in children. Journal of Clinical Pathology 23:7–18
     [Google Scholar]
  2. Alcami A., Smith G. L. 1995; Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. Journal of Virology 69:4633–4639
     [Google Scholar]
  3. Alwan W. H., Openshaw P. J. M. 1993; Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. Vaccine 11:431–437
     [Google Scholar]
  4. Alwan W. H., Kozlowska W. J., Openshaw P. J. M. 1994; Distinct types of lung disease caused by functional subsets of antiviral T cells. Journal of Experimental Medicine 179:81–89
     [Google Scholar]
  5. Amann V. L., Lerch R. A., Anderson K., Wertz G. W. 1992; Bovine respiratory syncytial virus nucleocapsid protein: mRNA sequence analysis and expression from recombinant vaccinia virus vectors. Journal of General Virology 73:999–1003
     [Google Scholar]
  6. Ball L. A., Young K. K. Y., Anderson K., Collins P. L., Wertz G. W. 1986; Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proceedings of the National Academy of Sciences USA: 83246–250
     [Google Scholar]
  7. Collins P. L., Purcell R. H., London W. T., Lawrence L. A., Chanock R. M., Murphy B. R. 1990; Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8:164–168
     [Google Scholar]
  8. Connors M., Collins P. L., Firestone C.-Y., Murphy B. R. 1991; Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by the M2 and N proteins is relatively short-lived. Journal of Virology 65:1634–1637
     [Google Scholar]
  9. Connors M., Collins P. L., Firestone C.-Y., Sotnokov A. V., Waitze A., Davis A. R., Hung P. P., Chanock R. M., Murphy B. R. 1992a; Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia- RSV recombinants or RSV. Vaccine 10:475–484
     [Google Scholar]
  10. Connors M., Kulkarni A. B., Collins P. L., Firestone C.-Y., Holmes K. L., Morse H. C., Murphy B. R. 1992b; Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8 + T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. Journal of Virology 66:1277–1281
     [Google Scholar]
  11. Crowe J. E., Collins P. L., London W. T., Chanock R. M., Murphy B. R. 1993; A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperaturesensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11:1395–1404
     [Google Scholar]
  12. Furze J., Wertz G., Lerch R., Taylor G. 1994; Antigenic heterogeneity of the attachment protein of bovine respiratory syncytial virus. Journal of General Virology 75:363–370
     [Google Scholar]
  13. Furze J. M., Roberts S. R., Wertz G. W., Taylor G. 1997; Antigenically distinct G glycoproteins of BRSV strains share a high degree of genetic homogeneity. Virology 231:48–58
     [Google Scholar]
  14. Gaddum R. M., Cook R. S., Wyld S. G., Lopez J. A., Bustos R., Melero J. A., Taylor G. 1996; Mutant forms of the F protein of human respiratory syncytial (RS) virus induce a cytotoxic T lymphocyte response but not a neutralizing antibody response and only transient resistance to RS virusinfection. JournalofGeneral Virology 77:1239–1248
     [Google Scholar]
  15. Kennedy H. E., Jones B. V., Tucker E. M., Ford N. J., Clarke S. W., Furze J., Thomas L. H., Stott E. J. 1992; Production and characterization of bovine monoclonal antibodies to respiratory syncytial virus. Journal of General Virology 69:3023–3032
     [Google Scholar]
  16. Kim H. W., Canchola J. G., Brandt C. D., Pyles G., Chanock R. M., Jensen K., Parrott R. M. 1969; Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. American Journal of Epidemiology 89:422–434
     [Google Scholar]
  17. Lerch R. A., Anderson K., Wertz G. W. 1990; Nucleotide sequence analysis and expression from recombinant vectors demonstrate that the attachment protein G of bovine respiratory syncytial virus is distinct from that of human respiratory syncytial virus. Journal of Virology 64:5559–5569
     [Google Scholar]
  18. Lerch R. A., Anderson K., Amann V. L., Wertz G. W. 1991; Nucleotide sequence analysis of the bovine respiratory syncytial virus fusion protein mRNA and expression from a recombinant vaccinia virus. Virology 181:118–131
     [Google Scholar]
  19. Olmsted R. A., Elango N., Prince G. A., Murphy B. R., Johnson P. R., Moss B., Chanock R. M., Collins P. L. 1986; Expression of the glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: Comparison of the individual contributions of the F and G glycoproteins to host immunity. Proceedings of the National Academy of Sciences USA: 837462–7466
     [Google Scholar]
  20. Olmsted R. A., Buller R. M. L., Murphy B. R., Beeler J. A., Collins P. L. 1988; Evaluation in nonhuman primates of the safety, immuno- genicity, and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus. Vaccine 6:205–210
     [Google Scholar]
  21. Openshaw P. J. M., Pemberton R. M., Ball L. A., Wertz G. W., Askonas B. A. 1988; Helper T cell recognition of respiratory syncytial virus in mice. Journal of General Virology 69:305–312
     [Google Scholar]
  22. Openshaw P. J. M., Clarke S. L., Record F. M. 1992; Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. International Immunology 4:493–500
     [Google Scholar]
  23. Sharma A. K., Woldehiwet Z., Walrevans K., Letteson J. 1996; Immune responses of lambs to the fusion (F) glycoprotein of bovine respiratory syncytial virus expressed on insect cells with a recombinant baculovirus. Vaccine 14:773–779
     [Google Scholar]
  24. Small P. A., Smith G. L., Moss B. 1985; Intranasal vaccination with a recombinant vaccinia virus containing influenza hemagglutinin prevents both influenza virus pneumonia and nasal infection: intradermal vaccination prevents only viral pneumonia. In Vaccine 85 pp 175–176 Lerner R. A., Chanock R. M., Brown F. Edited by Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
     [Google Scholar]
  25. Stott E. J., Taylor G. 1985; Respiratory syncytial virus. Brief review. Archives of Virology 84:1–52
     [Google Scholar]
  26. Stott E. J., Thomas L. H., Taylor G., Collins A. P., Jebbett J., Crouch S. 1984; A comparison of three vaccines against respiratory syncytial virus in calves. Journal of Hygiene, Cambridge 93:251–261
     [Google Scholar]
  27. Stott E. J., Taylor G., Ball L. A., Anderson K., Young K. K. Y., King A. M. Q., Wertz G. W. 1987; Immune and histological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. Journal of Virology 61:3855–3861
     [Google Scholar]
  28. Takao S.-I., Kiyotani K., Sagaguchi T., Fujii Y., Seno M., Yoshida T. 1997; Protection of mice from respiratory Sendai virus infection by recombinant vaccinia viruses. Journal of Virology 71:832–838
     [Google Scholar]
  29. Taylor G., Stott E. J., Bew M., Fernie B. F., Cote P. J., Collins A. P., Hughes M., Jebbett J. 1984; Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52:137–142
     [Google Scholar]
  30. Taylor G., Stott E. J., Thomas L. H. 1987; Lymphocyte transformation response of calves to respiratory syncytial virus. Journal of Medical Virology 22:333–344
     [Google Scholar]
  31. Taylor G., Stott E. J., Furze J., Ford J., Sopp P. 1992; Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies. Journal of General Virology 73:2217–2223
     [Google Scholar]
  32. Taylor G., Thomas L. H., Wyld S. G., Furze J., Sopp P., Howard C. J. 1995; Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves. Journal of Virology 69:6658–6664
     [Google Scholar]
  33. Thomas L. H., Gourlay R. N., Stott E. J., Howard C. J., Bridger J. C. 1982; A search for new microorganisms in calf pneumonia by the inoculation of gnotobiotic calves. Research in Veterinary Science 33:170–182
     [Google Scholar]
  34. Thomas L. H., Stott E. J., Collins A. P., Jebbett J. 1984; Experimental pneumonia in gnotobiotic calves produced by respiratory syncytial virus. British Journal of Experimental Pathology 65:19–28
     [Google Scholar]
  35. Wertz G. W., Stott E. J., Young K. K. Y., Anderson K., Ball L. A. 1987; Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. Journal of Virology 61:293–301
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-12-3195
Loading
Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions
J. Gen. Virol. 78, 3195 (1997); https://doi.org/10.1099/0022-1317-78-12-3195
/content/journal/jgv/10.1099/0022-1317-78-12-3195
/content/journal/jgv/10.1099/0022-1317-78-12-3195
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error